PTEN and prostate cancer: There is debate as to the best method of reporting low PTEN expression/loss of function, with the most frequent method reported being immunohistochemistry (IHC) [4], although more recently copy number alterations (CNA) in PTEN have been used to assess prognosis in prostate cancer [11].